Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer

por Lindsay, C. R., Le Moulec, S., Billiot, F., Loriot, Y., Ngo-Camus, M., Vielh, P., Fizazi, K., Massard, C., Farace, F.
Publicado 2016

A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours

por Boven, E, Massard, C, Armand, J P, Tillier, C, Hartog, V, Brega, N M, Countouriotis, A M, Ruiz-Garcia, A, Soria, J C
Publicado 2010

Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?

por Massard, C, Voigt, J-J, Laplanche, A, Culine, S, Lortholary, A, Bugat, R, Theodore, C, Priou, F, Kaminsky, M-C, Lesimple, T, Pivot, X, Coudert, B, Douillard, J-Y, Merrouche, Y, Fizazi, K
Publicado 2007

Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?

por Massard, C, Voigt, J-J, Laplanche, A, Culine, S, Lortholary, A, Bugat, R, Theodore, C, Priou, F, Kaminsky, M-C, Lesimple, T, Pivot, X, Coudert, B, Douillard, J-Y, Merrouche, Y, Fizazi, K
Publicado 2008

A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas

por Farace, F, Massard, C, Vimond, N, Drusch, F, Jacques, N, Billiot, F, Laplanche, A, Chauchereau, A, Lacroix, L, Planchard, D, Le Moulec, S, André, F, Fizazi, K, Soria, J C, Vielh, P
Publicado 2011

Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone

por Massard, C., Mateo, J., Loriot, Y., Pezaro, C., Albiges, L., Mehra, N., Varga, A., Bianchini, D., Ryan, C. J., Petrylak, D. P., Attard, G., Shen, L., Fizazi, K., de Bono, J.
Publicado 2017

Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials

por Nassif, E.F., Blay, J.-Y., Massard, C., Dufresne, A., Brahmi, M., Cassier, P., Ray-Coquard, I., Pautier, P., Leary, A., Sunyach, M.-P., Bahleda, R., Levy, A., Le Pechoux, C., Honoré, C., Mir, O., Le Cesne, A.
Publicado 2022

1617P Sustained cancer clinical trial activity during the COVID-19 pandemic

por Bayle, A., Baldini, C., Romano, P. Martin, Michot, J-M., Champiat, S., Bahleda, R., Gazzah, A., Marabelle, A., Verlingue, L., Geraud, A., Morel, D., Michiels, S., Ribrag, V., Hollebecque, A., Albiges, L., Besse, B., Soria, J-C., Massard, C., Barlesi, F., Postel-Vinay, S.
Publicado 2021

Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study

por Baldini, C., Charton, E., Schultz, E., Auroy, L., Italiano, A., Robert, M., Coquan, E., Isambert, N., Moreau, P., Le Gouill, S., Le Tourneau, C., Ghrieb, Z., Kiladjian, J.J., Delord, J.P., Roca, C. Gomez, Vey, N., Barlesi, F., Lesimple, T., Penel, N., Soria, J.C., Massard, C., Besle, S.
Publicado 2022

Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 study

por Charton, E., Baldini, C., Fayet, Y., Schultz, E., Auroy, L., Vallier, E., Italiano, A., Robert, M., Coquan, E., Isambert, N., Moreau, P., Touzeau, C., Le Tourneau, C., Ghrieb, Z., Kiladjian, J.-J., Delord, J.-P., Gomez Roca, C., Vey, N., Barlesi, F., Lesimple, T., Penel, N., Soria, J.-C., Massard, C., Besle, S.
Publicado 2023

Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study

por Simonelli, M., Garralda, E., Eskens, F., Gil-Martin, M., Yen, C.-J., Obermannova, R., Chao, Y., Lonardi, S., Melichar, B., Moreno, V., Yu, M.-L., Bongiovanni, A., Calvo, E., Rottey, S., Machiels, J.-P., Gonzalez-Martin, A., Paz-Ares, L., Chang, C.-L., Mason, W., Lin, C.-C., Reardon, D.A., Vieito, M., Santoro, A., Meng, R., Abbadessa, G., Menas, F., Lee, H., Liu, Q., Combeau, C., Ternes, N., Ziti-Ljajic, S., Massard, C.
Publicado 2022